American Senior Communities, the largest nursing home company in Indiana, has agreed to the settlement to resolve allegations that it violated federal laws by submitting false claims to the Medicare program.
Read More
The fines are one way Medicare is clamping down on hospitals, using penalties and incentives authorized by the Affordable Care Act to push for better outcomes, fewer safety problems and a lower number of readmissions.
Read More
The FDA has agreed to speed up review of donanemab, but the Centers for Medicare and Medicaid Services is moving to limit reimbursement for drugs in this class to only patients in clinical trials.
Read More
In Indiana last year, dozens of insurers across the state rolled out plans hoping to get a sizable piece of the fast-growing market.
Read More
Rural hospitals are among those that are most affected by the financial challenges facing health care institutions in Indiana, according to a new report released by the Indiana Hospital Association.
The latest negotiated prices apply to some of the prescription medications on which Medicare spends the most money.
The government says the lab billed Medicare for tests that were unnecessary or tied to improper referral arrangements.
Business leaders say health insurance is causing heartburn among many small employers, forcing some to consider dropping coverage altogether.
The deal is seen as one of the most significant in the administration’s current drug-pricing push, given the potential effect on public health and spending on health care.
Other parts of Indiana’s HIP 3.0 proposal are still under consideration, including an expansion on provider taxes, cost-sharing requirements and wellness incentives.
Hospital leaders who spoke with Inside INdiana Business emphasized the bill wouldn’t increase funding, it would give hospitals access to funding that’s already been allocated.
Trump administration officials have offered mixed messages about GLP-1s and whether they should be relied upon for weight loss by obese and overweight Americans.
Prosecutors say the organization bought more than 30 previously legitimate U.S. companies and turned them from lawful businesses into consistent vehicles for fraud.
Gov. Mike Braun’s new initiative borrows from Kennedy’s “Make America Healthy Again” slogan, which Kennedy, the U.S. health secretary, borrowed from President Donald Trump’s campaign.
The plan means cuts at the Food and Drug Administration, the Centers for Disease Control and Prevention, the National Institutes of Health, and the Centers for Medicare and Medicaid Services.
While the proposed rule would give millions of people access to weekly injectables like Eli Lilly and Co.’s Zepbound that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.
At stake are billions of dollars in bonuses that the Centers for Medicare and Medicaid Services awards to insurers that achieve a certain start rating on their Medicare Advantage scores.
Last month, the federal Medicare program proposed a 2.9% cut to physician pay for 2025. That marked the fifth straight year that regulators proposed cutting payments to doctors for thousands of services, from stitching a wound to replacing a knee.
Some of America’s seniors will see their out of pocket costs fall for more than five dozen drugs—including treatments for osteoporosis and cancer—as part of the White House’s crackdown on rising pharmaceutical prices.
An improving economy has contributed to changed projected depletion dates, according to the annual Social Security and Medicare trustees report Monday. Still, officials warned that policy changes are needed lest the programs become unable to pay full benefits to retiring Americans.
Rarely a day goes without President Joe Biden mentioning insulin prices and promoting a $35 price cap for the medication for Americans on Medicare. The reality is more complicated.
Obesity drugs like Wegovy and Eli Lilly’s Zepbound are showing promising results in helping people shed pounds. But a law bans Medicare from paying for weight loss drugs. Now, drugmakers and a bipartisan coalition of lawmakers are gearing up to push for that to change next year.
If history is any guide, there will be plenty of high-budget television ads from national and local insurance plans looking to boost their rolls. But the Centers for Medicare & Medicaid Services is cracking down on misleading pitches.
The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
